We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Achieves Milestone in Osteoporosis Collaboration with Lilly
News

Galapagos Achieves Milestone in Osteoporosis Collaboration with Lilly

Galapagos Achieves Milestone in Osteoporosis Collaboration with Lilly
News

Galapagos Achieves Milestone in Osteoporosis Collaboration with Lilly

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Achieves Milestone in Osteoporosis Collaboration with Lilly"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that it has reached a milestone in its osteoporosis collaboration with Eli Lilly and Company, triggering a payment of €2.5 million from Lilly.

In December 2007, Lilly and Galapagos initiated an alliance to develop new medicines for the treatment of osteoporosis. The agreement provides Lilly access to 12 of Galapagos' novel target based programs in osteoporosis, with Galapagos responsible for the development of drug candidates through to Phase IIa clinical Proof of Concept.

The milestone announced is the result of one of these programs reaching the next phase of medicinal chemistry optimization. To date, Galapagos has received a total of €3.9 million in milestone payments from Lilly under the alliance.
Advertisement